Document and Entity Information	12 Months Ended
Document and Entity Information	Dec. 31, 2018 shares
Document and Entity Information [Abstract]
Entity Registrant Name	Affimed N.V.
Entity Central Index Key	0001608390
Document Type	20-F
Document Period End Date	Dec. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding	62,430,106
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY

Consolidated Statement of Comprehensive Loss - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Statement of comprehensive income [abstract]
Revenue	€ 23,735	€ 2,010	€ 6,314
Other income - net	1,515	205	145
Research and development expenses	(35,148)	(21,489)	(30,180)
General and administrative expenses	(9,638)	(7,986)	(8,323)
Operating loss	(19,536)	(27,260)	(32,044)
Finance income / (costs) - net	60	(2,983)	(230)
Loss before tax	(19,476)	(30,243)	(32,274)
Income taxes	(1)	20	58
Loss for the period	(19,477)	(30,223)	(32,216)
Other comprehensive income Items that will not be reclassified to profit or loss
Equity investments at fair value OCI - net change in fair value	(4,731)
Other comprehensive income	(4,731)
Total comprehensive loss	€ (24,208)	€ (30,223)	€ (32,216)
Loss per share in per share (undiluted = diluted)	€ (0.32)	€ (0.69)	€ (0.97)
Weighted number of common shares outstanding	60,514,407	43,746,073	33,259,505

Consolidated Statement of Financial Position - EUR (€) € in Thousands	Dec. 31, 2018	Dec. 31, 2017
Non-current assets
Intangible assets	€ 56	€ 65
Leasehold improvements and equipment	1,414	1,113
Long term financial assets	3,825
Total non-current assets	5,295	1,178
Current assets
Cash and cash equivalents	94,829	39,837
Financial assets	13,974
Trade and other receivables	1,429	1,102
Inventories	260	241
Other assets	387	800
Total current assets	110,879	41,980
TOTAL ASSETS	116,174	43,158
Equity
Issued capital	624	468
Capital reserves	239,055	213,778
Fair value reserves	2,594
Accumulated deficit	(202,144)	(182,667)
Total equity	40,129	31,579
Non current liabilities
Borrowings	1,690	4,086
Contract liabilities	37,512
Total non-current liabilities	39,202	4,086
Current liabilities
Trade and other payables	9,425	4,180
Borrowings	3,083	3,083
Contract liabilities	24,335	230
Total current liabilities	36,843	7,493
TOTAL EQUITY AND LIABILITIES	€ 116,174	€ 43,158

Consolidated Statement of Cash Flows - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Cash flow from operating activities
Loss for the period	€ (19,477)	€ (30,223)	€ (32,216)
Adjustments for the period:
Income taxes	1	(20)	(58)
Depreciation and amortisation	403	351	369
Gain from disposal of leasehold improvements and equipment	25	(19)
Share based payments	2,035	1,943	3,545
Finance income / costs - net	(60)	2,983	230
Total	(17,073)	(24,985)	(28,130)
Change in trade and other receivables	(322)	1,140	(1,311)
Change in inventories	(19)	(44)	31
Change in other assets	121	(399)	(64)
Change in trade, other payables and deferred revenue	66,856	(1,018)	(2,177)
Cash from / (used in) operating activities	49,563	(25,306)	(31,651)
Interest received	218	106	102
Paid interest	(342)	(349)	(578)
Paid income tax	(1)
Net cash from / (used in) operating activities	49,438	(25,549)	(32,127)
Cash flow from investing activities
Purchase of intangible assets	(30)	(43)	(21)
Purchase of leasehold improvements and equipment	(691)	(625)	(238)
Cash received from the sale of leasehold improvements and equipment	1	35
Cash paid for investments in convertible note and warrants		(296)
Cash paid for investments in financial assets	(14,029)	(13,084)	(27,037)
Cash received from maturity of financial assets		22,063	18,147
Cash paid for investments in long term financial assets	(861)
Net cash from / (used for) investing activities	(15,610)	8,050	(9,149)
Cash flow from financing activities
Proceeds from issue of common shares	25,113	23,123	6
Transaction costs related to issue of common shares	(1,701)	(1,648)
Proceeds from borrowings		2,500	5,000
Transaction costs related to borrowings		(11)	(105)
Repayment of borrowings	(2,917)	(167)	(5,137)
Cash flow from / (used for) financing activities	20,495	23,797	(236)
Exchange-rate related changes of cash and cash equivalents	669	(1,867)	179
Net changes to cash and cash equivalents	54,323	6,297	(41,512)
Cash and cash equivalents at the beginning of the period	39,837	35,407	76,740
Cash and cash equivalents at the end of the period	€ 94,829	€ 39,837	€ 35,407

Consolidated Statement of Changes in Equity - EUR (€)
€ in Thousands

Issued Capital

Capital Reserves

Fair Value Reserves

Accumulated Deficit

Total

Balance, beginning at Dec. 31, 2015

€ 333

€ 187,169

€ (120,228)

€ 67,274

Issue of common shares

^[1]

Equity-settled share based payment awards

3,545

Issue of warrant note (loan Silicon Valley Bank)

142

Loss for the period

(32,216)

Balance, ending at Dec. 31, 2016

333

190,862

(152,444)

38,751

Issue of common shares

135

20,922

21,057

Equity-settled share based payment awards

1,943

Issue of warrant note (loan Silicon Valley Bank)

Loss for the period

(30,223)

Balance, ending at Dec. 31, 2017

468

213,778

(182,667)

31,579

Issue of common shares

156

23,171

23,327

Exercise of share based payment awards

Equity-settled share based payment awards

2,035

Loss for the period

(19,477)

Other comprehensive income

€ (4,731)

(4,731)

Balance, ending at Dec. 31, 2018

€ 624

€ 239,055

€ 2,594

€ (202,144)

€ 40,129

[1]	Issue of 3,341 shares

- Definition

The amount of residual interest in the assets of the entity after deducting all its liabilities.

+ References + Details

- Definition

The total of income less expenses, excluding the components of other comprehensive income. [Refer: Other comprehensive income]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2017-01-01
-Paragraph 18
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&num=7&date=2017-03-01&anchor=para_18_b&doctype=Standard
-URIDate 2017-03-09

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2017-01-01
-Paragraph 24
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=1&date=2017-03-01&anchor=para_24_b&doctype=Standard
-URIDate 2017-03-09

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2017-01-01
-Paragraph 32
-Subparagraph a
-Clause ii
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=1&date=2017-03-01&anchor=para_32_a_ii&doctype=Standard
-URIDate 2017-03-09

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2017-01-01
-Paragraph 28
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=8&date=2017-03-01&anchor=para_28_b&doctype=Standard
-URIDate 2017-03-09

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2017-01-01
-Paragraph 23
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=8&date=2017-03-01&anchor=para_23&doctype=Standard
-URIDate 2017-03-09

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2017-01-01
-Paragraph B10
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=12&date=2017-03-01&anchor=para_B10_b&doctype=Appendix&seq=2
-URIDate 2017-03-09

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2017-01-01
-Paragraph 106
-Subparagraph d
-Clause i
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&num=1&date=2017-03-01&anchor=para_106_d_i&doctype=Standard
-URIDate 2017-03-09

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Note Effective on first application of IFRS 9
-Name IFRS
-Number 4
-IssueDate 2017-01-01
-Paragraph 39L
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=4&date=2017-03-01&anchor=para_39L_e&doctype=Standard
-URIDate 2017-03-09

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2017-01-01
-Paragraph 81A
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&num=1&date=2017-03-01&anchor=para_81A_a&doctype=Standard
-URIDate 2017-03-09

+ Details

1. Reporting Entity	12 Months Ended
1. Reporting Entity	Dec. 31, 2018
Reporting Entity
Reporting Entity	1. Reporting entity Affimed N.V. is a Dutch company with limited liability (naamloze vennootschap) and has its corporate seat in Amsterdam, the Netherlands. The consolidated financial statements are comprised of Affimed N.V., and its controlled (and wholly owned) subsidiaries Affimed GmbH, Heidelberg, Germany, AbCheck s.r.o., Plzen, Czech Republic, Affimed Inc., Delaware, USA and AbCheck Inc., Delaware, USA (together “Affimed” or the “Group”). Affimed is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. The Group’s product candidates are developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body’s own immune defenses to fight tumor cells. Affimed has its own research and development programs, strategic collaborations and service contracts, where the Group is performing research services for third parties.

2. Basis of Preparation - Consolidated Financial Statements	12 Months Ended
	Dec. 31, 2018
Basis Of Preparation Consolidated Financial Statements
Basis of Preparation - Consolidated Financial Statements	2. Basis of preparation – consolidated financial statements Statement of compliance The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (IFRS). The consolidated financial statements were authorized for issuance by the management board on March 25, 2019. Basis of measurement The consolidated financial statements have been prepared on the historical cost basis except for financial instruments measured at fair value (see note 12) and monetary assets and liabilities denominated in foreign currencies which are translated at period-end exchange rates. The Group did not opt for a valuation of liabilities at fair value through profit or loss. Consolidation The Group controls an entity when it has power over the investee, is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. A subsidiary is consolidated from the date on which control is obtained by the Group. It is de-consolidated from the date control ceases. Intercompany transactions, balances and unrealized gains on transactions between group companies are eliminated. Functional and presentation currency The consolidated financial statements are presented in euro, which is also the subsidiaries’ functional currency. All financial information presented in euro has been rounded to the nearest thousand (abbreviated €) or million (abbreviated € million). Presentation of consolidated statements of comprehensive loss As a clinical-stage biopharmaceutical company with a primary focus on research and development activities, cost of sales and gross profit are not considered meaningful measures for Affimed and therefore are not presented. See note 3 for the Group’s accounting policies related to revenue recognition and research and development expenses. Foreign currency transactions Transactions denominated in currencies other than the euro are translated at exchange rates at the date of the transaction. Monetary assets and liabilities denominated in currencies other than the euro are translated at the exchange rate at the date of the consolidated statement of financial position. The foreign currency gain or loss on monetary items is the difference between amortized cost in the functional currency at the beginning of the period, adjusted for effective interest and payments during the period, and the amortized cost in foreign currency translated at the exchange rate at the end of the reporting period. Foreign currency gains or losses that relate to borrowings, cash and cash equivalents and financial assets, except for financial instruments at fair value through other comprehensive income are presented in the statement of comprehensive loss within ‘Finance income / (costs) - net’. All other foreign exchange gains and losses are presented in the statement of comprehensive loss within ‘Other income – net’.

3. Significant Accounting Policies

12 Months Ended

Dec. 31, 2018

Significant Accounting Policies

Significant Accounting Policies

3. Significant accounting policies

The accounting policies set out below have been applied consistently to all periods presented in these consolidated financial statements.

Revenue recognition

The Group generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Such services are performed on a “best efforts” basis without a guarantee of technological or commercial success. For some research programs, Affimed entered into collaborations with other companies that provides the Group with funding or other resources such as access to technologies. From time to time, the Group also licenses its intellectual property to third parties who use it to develop product candidates.

Collaboration and license agreements are evaluated to determine whether they involve multiple promises that represent separate performance obligations. Such agreements may comprise more than one research program, platform licenses or intellectual property licenses originally generated by the Group. Usually each of those promises is considered to meet the definition of a separate performance obligation.

The total consideration is generally allocated to separate performance obligations based on relative stand-alone selling prices. Usually sales prices for research and development activities and licenses are not directly observable or highly variable across customers. Therefore, we use estimation techniques to determine stand-alone selling prices for such services and licenses. The stand-alone selling prices for research activities are determined based on an expected cost plus a margin approach. For licenses of intangible assets where little or no incremental costs are incurred in providing such licenses a residual approach is used.

Performance obligations from research programs are satisfied over time because the work performed by the Group either enhances a license that the customer already controls or because the work does not result in an asset with an alternative use for the Group due to contractual restrictions.

Therefore, revenue for such performance obligations is recognized according to the stage of completion measured by reference to costs incurred in relation to anticipated total costs of the research program.

Platform licenses or intellectual property licenses originally generated by the Group are recognized at a point in time if their nature is a right to use the intellectual property as it exists at the point in time at which the license is granted. This is usually the case when there is no significant continuing involvement by the Group. In these cases, revenue is recognized when control of the license is transferred. Control is considered to be transferred when the customer received all necessary documents and information to begin to use and benefit from the license.

Platform licenses or intellectual property licenses originally generated by the Group are recognized over time if their nature is to access the intellectual property as it exists throughout the license period. This might be the case when there is significant continuing involvement by the Group. In these cases, revenue is recognized on a straight line basis until the use of the license by the customer ends.

Payments received from customers commonly include non-refundable upfront payments that are initially recognized as a contract liability, and subsequently recognized as revenue as the related performance obligation is fulfilled. The Group concluded that non-refundable upfront payments do not include financing components because the advance payments arise for reasons other than the provision of financing.

In addition, payment terms may also include payments to be received from customers at a later point in time upon the achievement of certain milestones.

Milestone payments are contingent upon the achievement of contractually stipulated targets. The achievement of these targets or milestones depends largely on meeting specific requirements laid out in the respective agreement. Milestone payments are included in the transaction price when it is highly probable that a significant reversal of revenue recognized will not occur when the uncertainty associated with the milestone is subsequently resolved. In the Group’s view uncertainty is sufficiently resolved only when the milestone is reached. Reaching a milestone will result in a cumulative catch up of revenue for the performance to date.

The Group distinguishes development and registration milestones and sales based milestones. Whereas development and registration milestone payments are generally recognized on reaching the defined milestones, revenues for sales based milestones are recognized on achievement of contractually stipulated underlying revenues.

Research and development

Costs incurred related to research activities are expensed in the period when they are incurred. Costs incurred on development projects are recognized as intangible assets beginning on the date it can be established that it is probable that future economic benefits attributable to the asset will flow to the Group considering its technological and commercial feasibility. Given the current stage of the development of the Group’s candidates and technologies, no development expenditures have been capitalized in any of the periods presented in these consolidated financial statements. Intellectual property-related costs for patents are part of the expenditure for the research and development projects. Therefore, registration costs for patents are recognized as expensed when incurred as long as the research and development project concerned does not meet the criteria for capitalization.

Employee benefits

(i)

Short-term employee benefits

Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided.

A liability is recognized for the amount expected to be paid under a short-term cash bonus, if (a) the Group has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee, and (b) the obligation can be estimated reliably.

(ii)

Share-based payment transactions

The Group’s share-based payment awards outstanding as of December 31, 2017 and 2018, are classified as equity-settled share-based plans. The fair value of share-based equity-settled awards granted to employees is measured at grant date and compensation cost is recognized over the vesting period with a corresponding increase in equity. Share-based payment awards with non-employees are measured and recognized when services are received. Fair value is estimated using the Black-Scholes-Merton formula. The formula determines the value of an option based on input parameters like the value of the underlying instrument, the exercise price, the expected volatility of share price returns, dividends, the risk-free interest rate, the expected forfeiture rate and the time to maturity of the option. The number of stock options expected to vest is estimated at each measurement date.

Government grants

The Group receives certain government grants that support its research effort in specific projects. These grants are generally provided in the form of reimbursement of approved costs incurred as defined in the respective grants. Income in respect of grants also includes contributions towards the costs of research and development. Income is recognized when costs under each grant are incurred in accordance with the terms and conditions of the grant and the collectability of the receivable is reasonably assured.

Government grants relating to costs are deferred and recognized in the income statement over the period necessary to match them with the costs they are intended to compensate. When the cash in relation to recognized government grants is not yet received the amount is included as a receivable on the statement of financial position.

The Group recognizes income from government grants under ‘Other income - net’ in the consolidated statement of comprehensive loss.

Lease payments

Payments made under operating leases are recognized in profit or loss on a straight-line basis over the term of the lease.

Finance income and finance costs

Finance income comprises interest income from interest bearing bank deposits. Interest income is recognized as it accrues using the effective interest method.

Finance costs comprise interest expense on borrowings and, in 2016, includes losses from early extinguishment of debt.

Financial instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

(i)

Non-derivative financial assets

The Group’s non-derivative financial assets include preferred shares in Amphivena, trade and other receivables, cash and cash equivalents and certificates of deposit at banks with original maturities of more than three months.

Receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. Those debt instruments are hold to collect solely payments of principal and interest. The Group decided to not apply the fair value through OCI option for those instruments. They are included in current assets and are subsequently carried at amortized cost.

Cash and cash equivalents comprise cash balances and call deposits with original maturities of three months or less.

The Group holds preferred shares in Amphivena designated at fair value through other comprehensive income (see note 12)

(ii)

Non-derivative financial liabilities

The Group’s classes of financial liabilities are borrowings and trade and other payables. The Group initially recognizes non-derivative financial liabilities on the date that they are originated and measures them at amortized cost using the effective interest rate method. The Group derecognizes a financial liability when its contractual obligations are discharged, cancelled or expire.

(iii)

Compound financial instruments

The Group entered into certain loan agreements pursuant to which it issued warrants to purchase common shares of the Group at the option of the respective holders (see note 17). The number of shares to be issued does not vary with changes in their fair value.

The liability component of the loans was recognized initially at the fair value of a similar liability without a warrant. The equity component was recognized initially at the difference between the fair value of the compound financial instrument as a whole and the fair value of the liability component. Subsequent to initial recognition, the liability component is measured at amortized cost using the effective interest method. The equity component is not re-measured subsequent to initial recognition.

In 2017, the Group held a convertible note agreement (see note 12). The Group designated the combined contract consisting of the loan component and the conversion feature embedded in the loan agreement at fair value through profit and loss and recognized changes of fair value re-measured on a recurring basis in ‘Finance income / (costs) – net.’ In December 2018, the notes were converted into shares

As at December 31, 2017, in connection with the convertible note described above, the Group received warrants to purchase common shares of Amphivena Therapeutics Inc., South San Francisco, USA (“Amphivena”) at a specified price (see note 12). Initially, the warrants were recognized at fair value. Subsequently the fair value was re-measured on a recurring basis with changes recognized in ‘Finance income / (costs) – net.’ In 2018, the warrants were cancelled.

Impairment

(i)

Trade and other receivables

Trade and other receivables at amortized cost are subject to the expected credit loss model according to IFRS 9. The Group’s exposure to credit risk is influenced mainly by the individual characteristics of each customer. However, management also considers the factors that may influence the credit risk of its customer base, including the default risk associated with the industry and country in which customers operate.

Affimed determines the counterparties’ lifetime expected credit losses that result from all possible default events over the expected life of a financial instrument based on an estimated rating and corresponding probability of default rates according to the Bloomberg database.

In addition, trade and other receivables are assessed at each reporting date to determine whether there is objective evidence that they are impaired. Trade or other receivables are impaired if objective evidence indicates that a loss event has occurred after the initial recognition of the receivable, and such loss event had a negative effect on the estimated future cash flows of that receivable that can be estimated reliably. Loss events include indications that a debtor is experiencing significant financial difficulty, default or delinquency in interest or principal payments, the probability that they will enter bankruptcy or other financial reorganization.

All receivables are assessed for specific impairment. Losses are recognized in profit or loss and reflected in an allowance account against receivables. When a subsequent event causes the amount of impairment loss to decrease, the decrease in impairment loss is reversed through profit or loss. No impairments or reversals of impairments were recognized in 2016, 2017 or 2018.

(ii)

Intangible assets and leasehold improvements and equipment

Assets that are subject to depreciation or amortization are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount may not be recoverable. An impairment loss is recognized as the amount by which an asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs of disposal and value in use. Non- financial assets that were previously impaired are reviewed for possible reversal of the impairment at each reporting date.

Income taxes

Income taxes comprise current and deferred tax. Current and deferred taxes are recognized in profit or loss except to the extent that it relates to items recognized directly in equity or in other comprehensive loss.

Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the reporting date, and adjustments to taxes payable in respect of previous years.

Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is not recognized for temporary differences associated with assets and liabilities if the transaction which led to their initial recognition is a transaction that is not a business combination and that affects neither accounting nor taxable profit or loss.

Deferred tax is measured at tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date.

Deferred tax assets and liabilities are presented net if there is a legally enforceable right to offset.

A deferred tax asset is recognized for unused tax losses, tax credits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized.

Fair Value Measurement

All assets and liabilities for which fair value is recognized in the consolidated financial statements are classified in accordance with the following fair value hierarchy, based on the lowest level input parameter that is significant on the whole for fair value measurement:

Level 1 – Prices for identical assets or liabilities quoted in active markets (non-adjusted)

Level 2 – Measurement procedures, in which the lowest level input parameter significant on the whole for fair value measurement is directly or indirectly observable for on the market

Level 3 – Measurement procedures, in which the lowest level input parameter significant on the whole for fair value measurement is not directly or indirectly observable for on the market

The carrying amount of all trade and other receivables, certificates of deposit, cash and cash equivalents and trade and other payables is a reasonable approximation of the fair value and therefore information about the fair values of those financial instruments has not been disclosed. The measurement of the fair value of the shares held by the group and note disclosure for the fair value of a loan (financial liability) is based on level 2 measurement procedures (see notes 12 and 17).

Loss per share

Loss per common share is calculated by dividing the loss of the period by the weighted average number of common shares outstanding during the period.

The Group has granted warrants under certain loan agreements (see note 17) and options under share-based payment programs (see note 16) which potentially have a dilutive effect; no instruments actually had a dilutive effect.

Critical judgments and accounting estimates

The preparation of the consolidated financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

In preparing these financial statements, the critical judgments made by management in applying the Group’s accounting policies resulted in the following accounting estimates:

(i)

Share-based payments

The fair value of stock options issued by Affimed N.V. is estimated using the Black-Scholes-Merton formula. The formula determines the value of an option based on input parameters like the value of the underlying instrument, the exercise price, the expected volatility of share price returns, dividends, the risk-free interest rate and the time to maturity of the option. The fair value of share-based equity-settled compensation plans is measured at grant date and compensation cost is recognized over the vesting period with a corresponding increase in equity. The number of stock options expected to vest is estimated at each measurement date.

On April 20, 2018, Affimed issued 240,000 options under its share-based-payment program, the vesting of which deviates from the standard 3‑year vesting scheme and depends upon a market parameter, which is the average price of Affimed shares during a certain period of time as described in Note 16. Incorporating the market condition in the fair value estimate requires the use of a simulation technique, which implies a higher uncertainty with regard to the estimated fair value. The Group determined the fair value of the awards at grant date to be €133.

(ii)

Revenue recognition

The Group’s contracts with customers contain multiple performance obligations. Judgment is required in determining whether a good or service is considered a separate performance obligation. If standalone selling prices are not directly observable, the Group allocates the transaction price to the performance obligations by reference to the expected cost plus a margin. In doing so, observable input data such as internal project plans and margins are used.

Elements of consideration in collaboration and license agreements are non-refundable up-front research funding payments, technology access fees and milestone payments. Generally, the Group has continuing performance obligations and therefore up-front payments are initially recognized as a contract liability, and the related revenues are subsequently recognized as the related performance obligation is fulfilled. Technology access fees are generally initially recognized as a contract liability and subsequently recognized over the expected term of the research service agreement on a straight-line basis.

The Group estimates that the achievement of a milestone reflects a stage of completion under the terms of the agreements and recognizes revenue when a milestone is achieved as then the uncertainty is resolved. If the research service is cancelled due to technical failure, the remaining contract liability from non-refundable upfront payments, if any, is recognized as revenue.

The determination of whether a performance obligation is satisfied at a point in time versus over time might also requires judgment.

(iii)

Accrued expenses

The Group obtains services from third parties who do not always invoice their (partial) performance as per the balance sheet date. If the Group is not invoiced or otherwise notified of the actual accrued cost for the services as of the reporting date, the amount of the services performed as of the balance sheet date has to be estimated. For this purpose, the Group periodically confirms the accuracy of its estimates with the service providers.

(iv)

Financial instruments

The Group recognized its preferred shares in Amphivena at fair value (level 2) as a long-term financial asset. As Amphivena is not a public company substantial judgment was required in estimating the fair value as at December 31, 2018 (see note 12). The Group based its judgment on information available for the valuation of the shares of Amphivena in its latest private financing in December 2018.

New standards and interpretations applied for the first time

The following amendments to standards and new or amended interpretations are effective for annual periods beginning on or after January 1, 2018, and have been applied in preparing these consolidated financial statements:


Standard/interpretation		Effective Date 1
IFRS 15 Revenue from Contracts with Customers		January 1, 2018
IFRS 9 Financial Instruments (2014)		January 1, 2018
Amendments to IFRS 2: Classification and Measurement of Share- based Payment Transactions		January 1, 2018
Annual Improvements to IFRS Standards 2014‑2016 Cycle (IFRS 1, IAS 28)		January 1, 2018

^1.

Shall apply for periods beginning on or after the date shown in the effective date column.

The nature and effect of the application of IFRS 9 and IFRS 15 are summarized below. The other amendments had no effect on the interim consolidated financial statements of the Group.

IFRS 9 (Financial Instruments)

Changes in accounting policies resulting from the adoption of IFRS 9 have been applied retrospectively with any differences in the carrying amounts arising from the transition being recognized in equity as at January 1, 2018.

Classification

The standard contains a new classification and measurement approach for financial instruments that reflects the business model in which assets are managed and their cash flow characteristics. Based on the new measurement requirements, Affimed recognized its shares in Amphivena at fair value, which were previously recognized at amortized cost according to IAS 39. The transition effect increased other comprehensive income by €7.3 million as of January 1, 2018 (see note 12). The Group classified the shares as at fair value through other comprehensive income (FVOCI). Future changes in fair value will be recognized in other comprehensive income, dividends will be recognized as income in profit or loss.

Combined financial instruments are measured at fair value with changes therein recognized as finance income / (costs).

Impairment

The newly introduced impairment rules replace the ‘incurred loss’ model in IAS 39 with a forward looking ‘expected credit loss’ (“ECL”) model. This requires considerable judgement as to how changes in economic factors affect ECLs, which will be determined on a probability-weighted basis. Under IFRS 9, the Group has decided to measure loss allowances on the following basis:

- Cash and cash equivalents and financial assets: The Group determines the counterparties’ 12‑month ECLs that result from possible default events within the 12 months after the reporting date based on the probability of default according to the Bloomberg database.

- Trade receivables: The Group determines the counterparties’ lifetime ECLs that result from all possible default events over the expected life of a financial instrument based on an estimated rating and corresponding probability of default rates according to the Bloomberg database.

Based on this methodology, incurred losses on cash and cash equivalents and on trade and other receivables as of January 1, 2018 had no material impact on the consolidated financial statements.

IFRS 15 (Revenue from contracts with customers)

IFRS 15 (Revenue from contracts with customers) establishes a comprehensive framework for determining whether, how much and when revenue is recognized. It replaces existing revenue recognition guidance, including IAS 18 Revenue, IAS 11 Construction Contracts and IFRIC 13 Customer Loyalty Programs.

The Group analyzed its collaboration agreements and service contracts in the scope of IFRS 15 to identify performance obligations and an appropriate revenue recognition pattern. The Group concluded that IFRS 15 has no impact on the revenue recognition policy and revenue from current collaboration and service agreements which is recognized according to the stage of completion. No differences between the previously applied IASs and IFRS 15 for all open contracts as of December 31, 2017 were noted. Therefore, no transition effect as of January 1, 2018 was recorded.

New standards and interpretations not yet adopted

The following new standards and amendments to standards are effective for annual periods beginning after December 31, 2018, and have not been applied in preparing these consolidated financial statements.


Standard/Amendment		Effective Date 1
IFRS 16 Leases		January 1, 2019
Amendments to IFRS 9: Prepayment Features with Negative Compensation		January 1, 2019
Amendments to IAS 28: Long-term Interests in Associates and Joint Ventures		January 1, 2019
Annual Improvements to IFRS Standards 2015‑2017 Cycle		January 1, 2019
Amendments to IAS 19: Plan Amendment, Curtailment or Settlement		January 1, 2019
Amendments to IAS 1 and IAS 8: Definition of Material		January 1, 2020

^1.

Shall apply for periods beginning on or after the date shown in the effective date column.

IFRS 16 (Leases)

The new standard specifies how to recognize, measure, present and disclose lease agreements. The standard provides a single lessee accounting model, requiring lessees to recognize assets and liabilities for all leases unless the lease term is 12 months or less or the underlying asset has a low value. Affimed will be required to recognize “right-of-use” assets related to its premises rented and certain equipment leased.

The Group has completed an assessment of the impact of IFRS 16 on its consolidated financial statements and has identified the Group’s leases including contractual payments, renewal options, and other terms. The most significant impact identified is that the Group will recognize new assets and liabilities for its operating leases of office space and research and development facilities. Based on the information currently available, the Group estimates that it will recognize right-of-use assets and corresponding lease liabilities of approximately €0.7 million as at January 1, 2019.

The other amended standards are not expected to have a significant effect on the consolidated financial statements of the Group.

4. Segment Reporting

12 Months Ended

Dec. 31, 2018

Segment Reporting

Segment Reporting

4. Segment reporting

(i)

Information about reportable segment

The Group is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The activities are either conducted as own project development or for third party companies. Management of resources and reporting to the chief operating decision maker is based on the Group as a whole.

(ii)

Geographic information

The geographic information below analyses the Group’s revenue and non-current assets by country. In presenting the following information, segment revenue has been based on the geographic location of the customers and segment assets were based on the geographic location of the assets.

Discovery activities and research services are conducted in both the Heidelberg and Plzen premises. Pre-clinical and clinical activities are conducted and coordinated from Heidelberg.


	2018	2017	2016
Revenue:
Germany	31	80	6
Europe	1,175	1,236	1,397
USA	22,529	694	4,911
	23,735	2,010	6,314

Non-current assets as of December 31:
Germany	1,224	957	618
Czech Republic	246	221	259
USA	3,825	—	—
	5,295	1,178	877

(iii)

Other revenue information


	2018	2017	2016
Major service lines:
Collaboration revenue	22,018	390	3,866
Service revenue	1,717	1,620	2,448
	23,735	2,010	6,314

Revenue:
Point in time	21,863	233	1,191
Over time	1,872	1,777	5,123
	23,735	2,010	6,314

(iv)

Major Customers

For the years ended December 31, 2016 and 2017, the Group’s revenue with three and four customers, respectively, exceeded 10% of total revenues. In 2018, the Group’s revenue with Genentech Inc. exceeded 10% of total revenues.

5. Revenue

12 Months Ended

Dec. 31, 2018

Revenue [abstract]

Revenue

5. Revenue

Collaboration agreement with Amphivena

Until July 2016, Affimed was party to a collaboration with Amphivena. The purpose of the collaboration was the development of a product candidate for hematological malignancies. The collaboration included a License and Development Agreement between Amphivena and Affimed, which expired when Amphivena obtained the approval of an investigational new drug application (IND) from the FDA in July 2016.

Pursuant to the license and development agreement between Affimed and Amphivena, Affimed granted a license to intellectual property and agreed to perform certain services for Amphivena related to the development of a product candidate for hematological malignancies. In consideration for the research and development work that was performed, Amphivena was required to pay to Affimed service fees totaling approximately €16 million payable according to the achievement of milestones and phase progressions as described under the license and development agreement. Since the expiration of the agreement, the parties have been closing out the collaboration by exchanging documentation and transferring materials and third-party contracts.

During the years ended December 31, 2016 and 2017, the Company recognized revenue upon achievement of milestones and for the performance of research and development services (net of Affimed’s share in funding Amphivena) totaling €3.4 million and €0.2 million, respectively.

Collaboration agreement The Leukemia & Lymphoma Society (LLS)

Affimed is party to a collaboration with LLS to fund the development of a specific product candidates (immune cell engagers). Under the terms of the agreement, LLS has agreed to contribute up to $4.4 million contingent upon the achievement of certain milestones.

In the event that the research and development is successful, Affimed must proceed with commercialization of the licensed product. If Affimed decides for business reasons not to continue the commercialization, Affimed must at its option either repay the amount funded or grant a license to LLS to enable LLS to continue with the development program. In addition, LLS is entitled to receive royalties from Affimed based on the Group’s future revenue from any licensed product, with the amount of royalties not to exceed three times the amount funded.

In June 2016, the research funding agreement with LLS was amended to reflect a shift to the development of combination therapeutic approaches so that the milestones now relate primarily to the development of a combination therapy.

During the years ended December 31, 2016, 2017 and 2018, the Group achieved several milestones and recognized revenue totaling €0.4 million, €0.2 million and €0.2 million, respectively.

Collaboration with Genentech Inc.

In August 2018, Affimed entered into a strategic collaboration agreement with Genentech Inc., headquartered in South San Francisco, USA. Under the terms of the agreement Affimed will develop novel NK cell engager-based immunotherapeutics to treat multiple cancers. The Genentech agreement became effective at the beginning of October 2018. Under the terms of the agreement, Affimed received $96.0 million (€83.2 million) in an initial upfront payment and committed funding on October 31, 2018. The Group recognized €21.8 million as revenue in 2018 and €61.4 million under contract liabilities, which will be recognized as revenue in subsequent periods.

Under the terms of the agreement, Affimed is eligible to receive up to an additional $5.0 billion over time, including payments upon achievement of specified development, regulatory and commercial milestones. Affimed is also eligible to receive royalties on any potential sales.

Research service agreements

AbCheck has entered into certain research service agreements. These research service agreements provide for non-refundable upfront technology access research funding or capacity reservation fees and milestone payments. The Group recognized revenue of €2.4 million, €1.6 million and €1.7 million during the years ended December 31, 2016, 2017 and 2018, respectively.

Contract balances

The following table provides information about receivables and contract liabilities from contracts with customers.


	January 1, 2018	December 31, 2018
Receivables	210	580
Contract liabilities	230	61,847

The total amount of €230 recognized in contract liabilities at the beginning of the period has been recognized as revenue for the period ended December 31, 2018.

The remaining performance obligations at December 31, 2018 are approximately €61.8 million and are expected to be recognized as revenue to a large extent over the next two years.

7. Research and Development Expenses

12 Months Ended

Dec. 31, 2018

Research And Development Expenses

Research and Development Expenses

7. Research and development expenses

The following table shows the different types of expenses allocated to research and development costs for the years ended December 31:


	2018	2017	2016
Third-party services	22,127	12,299	20,170
Personnel expenses	8,055	5,639	6,648
Legal, consulting and patent expenses	1,672	890	758
Cost of materials	1,140	994	1,028
Amortisation and depreciation	351	309	322
Operating lease expenses	401	345	297
Other expenses	1,402	1,013	957
	35,148	21,489	30,180

8. General and Administrative Expenses

12 Months Ended

Dec. 31, 2018

General And Administrative Expenses

General and Administrative Expenses

8. General and administrative expenses

The following table shows the different types of expenses allocated to general and administrative costs for the years ended December 31:


	2018	2017	2016
Personnel expenses	4,929	4,521	4,729
Legal, consulting and audit fees	2,881	1,945	2,210
Operating lease expenses	162	126	111
Other expenses	1,666	1,394	1,273
	9,638	7,986	8,323

9. Employee Benefits

12 Months Ended

Dec. 31, 2018

Employee Benefits

Employee Benefits

9. Employee benefits

The following table shows the items of employee benefits for the years ended December 31:


	2018	2017	2016
Wages and salaries	10,027	7,475	7,445
Social security costs	1,092	931	807
	11,119	8,406	8,252

The employer’s contributions to pension insurance plans of €502 (2017: €438, 2016: €362) are classified as payments under a defined contribution plan, and are recognized as an expense.

10. Finance Income and Finance Costs

12 Months Ended

Dec. 31, 2018

Finance Income And Finance Costs

Finance Income and Finance Costs

10. Finance income and finance costs

The following table shows the items of finance income and costs for the years ended December 31:


	2018	2017	2016
Interest Perceptive Loan Agreement (see note 17)	—	—	(762)
Other finance cost Perceptive Loan Agreement (see note 17)	—	—	(242)
Interest SVB Loan Agreement (see note 17)	(847)	(690)	(41)
Foreign exchange differences	651	(2,378)	691
Interest on certificates of deposit with maturities of more than three months (see note 13)	5	77	122
Other finance income/finance costs	251	8	2
Finance income/costs - net	60	(2,983)	(230)

11. Income Taxes

12 Months Ended

Dec. 31, 2018

Income Taxes

Income Taxes

11. Income taxes

The Group did not incur any material income tax in the periods presented. As of December 31, 2018 deferred tax liabilities from temporary differences result mainly from borrowings (€75; 2017: €152) and long term financial assets (€774). Deferred tax assets from differences resulting from trade and other receivables (€334; 2017: €259), intangible assets (€415; 2017: €405) and trade and other payables (€27; 2017: €17) have not been recognized as deferred tax assets as no sufficient future taxable profits or offsetting deferred tax liabilities are available.

A reconciliation between actual income taxes and the expected tax benefit from the loss before tax multiplied by the Group’s applicable tax rate is presented below for the years ended December 31:


	2018	2017	2016
Loss before tax	(19,476)	(30,243)	(32,274)
Income tax benefit at tax rate of 29.825 %	5,809	9,020	9,626
Adjustments due to impairment of deferred tax assets	(5,318)	(9,036)	(8,747)
Permanent differences	(462)	(93)	(948)
Adjustments for local tax rates	(34)	195	12
Non deductible expenses	(53)	16	154
Other	57	(82)	(38)
Income taxes	(1)	20	58

In Germany, Affimed has tax losses carried forward of €163.8 million (2017: €146.8 million) for corporate income tax purposes and of €163.4 million (2017: €146.4 million) for trade tax purposes that are available indefinitely for offsetting against future taxable profits of that entity. Restrictions on the utilization of tax losses in case of a change of control of ownership in Affimed were mitigated by the enactment of the Economic Growth Acceleration Act (Wachstumsbeschleunigungsgesetz 2009). According to the provisions of this act unused tax losses of a corporation as at the date of a qualified change in ownership are preserved to the extent they are compensated by an excess of the fair value of equity for tax purposes above its carrying amount of the Group. The maximum amount of tax losses at risk of being lost due to ownership changes is approximately €59 million. Deferred tax assets have not been recognized in respect of any losses carried forward as no sufficient taxable profits of Affimed are expected.

Tax losses of Abcheck amount to €423 as at December 31, 2018.

12. Long Term Financial Assets	12 Months Ended
12. Long Term Financial Assets	Dec. 31, 2018
Disclosure of financial assets [abstract]
Long Term Financial Assets	12. Long term financial assets As of January 1, 2018, the Group held preferred shares in Amphivena, which were previously recognized at amortized costs according to IAS 39. Due to the first-time adoption of IFRS 9 these shares are recognized at fair value through other comprehensive income. The initial recognition as of January 1, 2018 amounted to €7.3 million. As at December 5, 2018, following a reverse stock-split, the preferred shares were converted into 831,071 preferred shares at a conversion price of $3.59. On December 27, 2017, the Group signed a note purchase agreement with Amphivena (the “2017 note purchase agreement”) pursuant to which Amphivena issued to the Group a convertible note with a principal amount of $0.35 million (the “2017 note”) and warrants to purchase 46,667 common shares of Amphivena with an exercise price of $0.01 per common share. On June 22, 2018, the Group signed a second note purchase agreement with Amphivena (the “2018 note purchase agreement”) pursuant to which Amphivena issued to the Group a new convertible note with a principal amount of $1.0 million, and cancelled all warrants previously issued to the Group under the 2017 note purchase agreement. In December 2018, the principal amount of the convertible notes plus accrued interest totaling $1.4 million was converted at a conversion rate of $3.59 per share into 389,484 Class C preferred shares of Amphivena. As at December 31, 2018 the Group holds 1,220,555 preferred shares in Amphivena with a fair value of €3.8 million. The Group recognized losses from the change in fair value of €4.7 million including €32 exchange rate losses in other comprehensive income (OCI). Interest gains of €13 and exchange rate gains of €39 related to the convertible notes were recognized in profit and loss.

15. Equity	12 Months Ended
15. Equity	Dec. 31, 2018
Equity
Equity	15. Equity As of December 31, 2018, the share capital of €624 (2017: €468) is composed of 62,430,106 (2017: 46,791,352) common shares with a par value of €0.01. In the first quarter of 2018, the Group issued 2,373,716 common shares in connection with its at-the-market sales agreement for net proceeds of €3.8 million. On February 15, 2018, the Group issued 13,225,000 common shares in a public offering at a price of $2.00 per common share resulting in aggregate net proceeds of €19.7 million. On June 19, 2018, the authorized share capital was increased from €2,196 to €3,200 to consisting of 155,975,000 common shares and 155,975,000 cumulative preference shares, each with a par value of €0.01 per share.

16. Share Based Payments

12 Months Ended

Dec. 31, 2018

Share Based Payments

Share Based Payments

16. Share based payments

In 2014, an equity-settled share-based payment program was established by Affimed N.V. (ESOP 2014).

Under this program, the Group granted awards to certain members of the Management Board, the Supervisory Board, non-employee consultants and employees.

Share based payments with service condition

The majority of the awards vest in installments over three years and can be exercised up to 10 years after the grant date. The Group granted 1,436,075 awards in 2017 and 2,332,296 awards in 2018 to employees, the Management Board and others providing similar services (certain consultants).

In 2018, 424,688 ESOP 2014 awards were cancelled or forfeited due to termination of employment or termination of consulting agreements with non-employees (2017: 399,552), and 40,038 ESOP 2014 awards were exercised in 2018 at an average exercise price of $1.98.

As of December 31, 2018, 5,948,438 ESOP 2014 awards were outstanding (December 31, 2017: 4,080,868), 2,814,547 awards (December 31, 2017: 2,001,264) were vested. The options outstanding at December 31, 2018 had an exercise price in the range of $1.30 to $13.47 (2017: $1.80 to $13.47) and weighted average remaining contractual life of 9.3 years (2017: 8.4 years). In 2018, the Group estimated an annual forfeiture rate of 4.0% for unvested options.

Share based payments with market condition

On April 20, 2018, Affimed issued 240,000 options, of which each grant consists of three tranches that vest when the volume-weighted average share price (measured based on Affimed closing share prices over the preceding fifteen trading days) reaches a certain hurdle ($6.15, $8.20 and $10.25). Fair value of the awards at grant date amounts to €133 ($164 thousand) and the contractual life time of the options is two years. As at December 31, 2018 no options were exercisable.

Share based payment expense

In 2018, an expense of €2,035 was recognized affecting research and development expenses (€852) and general and administrative expenses (€1,183). In 2017, an expense of €1.943 was recognized affecting research and development expenses (€522) and general and administrative expenses (€1,421). In 2016, an expense of €3,545 was recognized affecting research and development expenses (€1,178) and general and administrative expenses (€2,367).

Fair value measurement

The fair value of options was determined using the Black-Scholes valuation model. The significant inputs into the valuation model of share based payment grants with service conditions are as follows (weighted average):


	2018			2017
Fair value at grant date	$	1.20		$	1.10
Share price at grant date	$	1.91		$	2.00
Exercise price	$	1.92		$	2.03
Expected volatility		72	%		70	%
Expected life		5.90			5.90
Expected dividends		0.00			0.00
Risk-free interest rate		0.34	%		(0.23)	%

Expected volatility is estimated based on the observed daily share price returns of a peer group measured over a historic period equal to the expected life of the awards.

17. Borrowings

12 Months Ended

Dec. 31, 2018

Borrowings [abstract]

Borrowings

17. Borrowings

Silicon Valley Bank

On November 30, 2016, the Group entered into a loan agreement with Silicon Valley Bank (the “SVB loan”) which provides the Group with a senior secured term loan facility originally for up to €10.0 million, which agreement was amended in May 2017 to provide that such amount would be available in three tranches. In December 2016, the Group drew an initial tranche of €5.0 million and in May 2017, a second tranche of €2.5 million; the availability of a third tranche of €2.5 million expired in September 2017 with such amount remaining undrawn.

Finance costs comprise the interest rate of one-month EURIBOR plus an applicable margin of 5.5%, with a floor of 5.5%, related one-time legal and arrangement fees of €236 and a final payment fee equal to 10% of the total principal amount to be paid with the last instalment. Pursuant to the loan agreement, the Group also granted the lender 166,297 and 53,395 warrants with an exercise price of $2.00 and $2.30 per share, respectively. Each warrant can be used to purchase common shares of Affimed at the respective exercise price for a period of ten years from the grant date. The fair value of the warrants of €192 less deferred taxes and transaction costs of €81 and €8, respectively, was recorded as an addition to capital reserves in equity. The fair value of the warrants was determined using the Black-Scholes-Merton valuation model, with an expected volatility of 75‑80% and an expected exercise period of five years to exercise of the warrant. The contractual maturity of the warrants is ten years.

The loan is secured by a pledge of 100% of Group’s ownership interest in Affimed GmbH, all intercompany claims owed to Affimed N.V. by its subsidiaries, and collateral agreements for all bank accounts, inventory, trade receivables and other receivables of Affimed N.V. and Affimed GmbH recognized in the consolidated financial statements with the following book values:


	Book value as of December 31,		Book value as of December 31,
	2018		2017
	Consolidated	thereof	Consolidated
	financial	assets	financial	thereof assets
	statements	pledged	statements	pledged
Leasehold improvements and equipment	1,414	1,174	1,113	891
Inventories	260	235	241	219
Trade and other receivables	1,429	1,007	1,102	328
Other assets	387	—	800	292
Financial assets	13,974	13,974	—	—
Cash and cash equivalents	94,829	92,933	39,837	38,726
	112,293	109,323	43,093	40,456

As of December 31, 2018 and 2017, the fair value of the liability did not differ significantly from its carrying amount (€4,773 and €7,169). The loan has a maturity date of May 31, 2020, repayment started in December 2017 with amortized payments of principal and interest in equal monthly installments. As of December 31, 2018, €3,083 (2017: €3,083) were classified as current liabilities.

19. Operating Leases and Other Commitments and Contingencies

12 Months Ended

Dec. 31, 2018

Operating Leases And Other Commitments And Contingencies

Operating Leases and Other Commitments and Contingencies

19. Operating leases and other commitments and contingencies

(i)

Lease and other commitments

The Group has entered into rental agreements for premises as well as into leases for vehicles and the use of licenses. These agreements have an average non-cancellable term of between one and four years with renewal options included in some contracts. In 2018, lease expenses of €562 and license fees of €124 have been recognized in consolidated statement of comprehensive income (2017: €472 and €174; 2016: €409 and €405).

Future minimum lease payment obligations under non-cancellable operating leases as of the reporting date are as follows:


	2018	2017
Within one year	637	470
Between one and five years	517	363
	1,154	833

(ii)

Contingencies

Affimed has entered into various license agreements that contingently trigger payments upon achievement of certain milestones and royalty payments upon commercialization of a product in the future.

20. Related Parties

12 Months Ended

Dec. 31, 2018

Related Parties

Related Parties

20. Related parties

(i)

Shareholders

As of December 31, 2018 and 2017, no shareholder holds more than 20% of the voting rights.

(ii)

Transactions with key management personnel

The compensation of managing directors and other key management personnel comprised of the following:


	2018	2017	2016
Short-term employee benefits	2,683	1,538	1,879
Termination benefits	—	—	430
Share-based payments	1,229	1,379	2,292
	3,912	2,917	4,601

Remuneration of Affimed’s managing directors comprises fixed and variable components and share-based payment awards. In addition, the managing directors receive supplementary benefits such as fringe benefits and allowances. In the case of an early termination, the managing directors receive a severance.

Compensation for other key management personnel comprises fixed and variable components and share-based payment awards.

The supervisory directors of Affimed N.V. received compensation for their services on the supervisory board of €382 (2017: €375; 2016: €350). In 2018, the Group recognized expenses for share-based payments for supervisory board members of €117 (2017: €144, 2016: €381).

Selected managing directors and supervisory directors entered into service and consulting agreements with the Group:

Dr. Ulrich Grau is a significant shareholder and Chairman of the Board of Directors of i-novion Inc., which was engaged by the Group to conduct preclinical services. In 2016, i-novion Inc. received related payments of €86.

Jens-Peter Marschner rendered consulting services amounting to €29 in 2016.

The following table provides the total amounts of outstanding balances related to key management personnel and supervisory directors:


	Outstanding balances
	December 31,	December 31,
	2018	2017
Martin Treder	9	—
Leila Alland	40	—
Thomas Hecht	21	19
Richard Stead	—	12
Berndt Modig	10	9
Ferdinand Verdonck	11	10
Ulrich Grau	21	17
Bernhard Ehmer	17	10

21. Financial Risk Management

12 Months Ended

Dec. 31, 2018

Financial Risk Management

Financial Risk Management

21. Financial risk management

(i)

Financial risk management objectives and policies

The Group’s principal financial instruments comprise cash and cash equivalents, certificates of deposit at commercial banks, a convertible loan, warrants and investor loans presented in borrowings. The main purpose of these financial instruments is to raise funds for the Group’s operations. The Group has various other financial assets and liabilities such as trade and other receivables and trade and other payables, which arise directly from its operations.

The main risks arising from the Group’s financial instruments are credit risk and liquidity risk. The measures taken by management to manage each of these risks are summarized below.

(ii)

Credit risk

The Group’s financial assets comprise to a large extent cash and cash equivalents. In addition, financial assets include shares, certificates of deposit, trade and other receivables and in 2017, a convertible loan and warrants. The total carrying amount of shares (€3.8 million), cash and cash equivalents (€94.8 million, 2017: €39.8 million), trade and other receivables (€1.4 million, 2017: €1.1 million), certificates of deposit (€14.0 million) and in 2017, convertible notes and warrants of Amphivena (€0.3 million), represents the maximum credit exposure of €114.1 million (2017: €41.2 million).

The cash and cash equivalents and certificates of deposit are held with banks, which are rated BBB+ to AA- based on Standard & Poor’s and Moody’s.

(iii)

Interest rate risk

The Group’s interest rate risk arises from cash accounts and long-term borrowings at variable rates.

Affimed entered into the SVB loan pursuant to which the Group borrowed €7.5 million with an outstanding balance of 4.8 million as at December 31, 2018, with a variable interest rate of an annual rate of 5.5% plus one-month EURIBOR, with EURIBOR deemed to equal zero percent if EURIBOR is less than zero percent. The Group does not expect the EURIBOR to exceed the floor of 0% within the foreseeable future, and considers the interest risk to be low.

Market interest rates on cash and cash equivalents as well as on term deposits were low in 2018, resulting in interest income of €264 in 2018. A shift in interest rates (increase or decrease) would not have a material impact on the loss of the Group.

(iv)

Other price risks

The fair value of the shares in Amphivena depends on the share price. The total exposure of the Group amounts to €3.8 million.

(v)

Foreign currency risk

Foreign exchange risk arises when future commercial transactions or recognized assets or liabilities are denominated in a currency that is not the entity’s functional currency.

The Group’s entities are exposed to Czech Koruna (CZK) and US Dollars (USD) and British Pound (GBP). The net exposure as of December 31, 2018 was €47,524 (2017: €18,768) and mainly relates to US Dollars.

In 2018, if the Euro had weakened/strengthened by 10% against the US dollar with all other variables held constant, the loss would have been €4,787 (2017: €1,887) higher/lower, mainly as a result of foreign exchange gains/losses on translation of US dollar-denominated financial assets. The Group considers a shift in the exchange rates of 10% as a realistic scenario.

Loss is more sensitive to movement in exchange rates shifts in 2018 than in 2017 because of the increased volume of US dollar-denominated transactions.

The following significant exchange rates have been applied during the year:


	2018	2017	2016
	CZK or	CZK or	CZK or
	USD/EUR	USD/EUR	USD/EUR
CZK - Average Rate	0.03899	0.03799	0.03699
CZK - Spot rate	0.03887	0.03916	0.03701

USD - Average Rate	0.84674	0.88519	0.90404
USD - Spot rate	0.87336	0.83382	0.94868

(vi)

Liquidity risk

Liquidity risk is the risk that the Group will encounter difficulties in meeting the obligations associated with its financial liabilities which are normally settled by delivering cash. The Group’s approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due.

The Group continually monitors its risk of a shortage of funds using short and mid-term liquidity planning. This takes account of the expected cash flows from all activities. The supervisory board undertakes regular reviews of the budget.

In 2016, 2017 and February 2018, Affimed raised significant funding that it estimates will enable the Group to fund operating expenses and capital expenditure requirements into 2021.

In 2015, the Group has entered into an at-the-market sales agreement with Cowen & Group, LLC under which €5.1 million in net proceeds has been raised in 2017.

In 2017, the Group issued 10,646,762 common shares in a public offering at a price of $1.80 per common share for net proceeds of €16.4 million.

In 2018, the Group issued 13,225,000 common shares in a public offering at a price of $2.00 per common share for net proceeds of approximately €19.7 million and 2,373,716 common shares in connection with its at-the-market sales agreement for net proceeds of €3.8 million (see note 15).

The Group expects to require additional funding to complete the development of the existing product candidates. In addition, the Group expects to require additional capital to commercialize the products if regulatory approval is received.

(vii)

Capital management

The primary objective of the Group’s capital management is to ensure that it maintains its liquidity in order to finance its operating activities and meet its liabilities when due.

The Group manages its capital structure primarily through equity.

3. Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2018

Significant Accounting Policies Policies

Revenue Recognition

Revenue recognition

In addition, payment terms may also include payments to be received from customers at a later point in time upon the achievement of certain milestones.

Research and Development

Research and development

Employee Benefits

Employee benefits

(i)

Short-term employee benefits

Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided.

(ii)

Share-based payment transactions

Government Grants

Government grants

The Group recognizes income from government grants under ‘Other income - net’ in the consolidated statement of comprehensive loss.

Lease Payments

Lease payments

Payments made under operating leases are recognized in profit or loss on a straight-line basis over the term of the lease.

Finance Income and Finance Costs

Finance income and finance costs

Finance income comprises interest income from interest bearing bank deposits. Interest income is recognized as it accrues using the effective interest method.

Finance costs comprise interest expense on borrowings and, in 2016, includes losses from early extinguishment of debt.

Financial Instruments

Financial instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

(i)

Non-derivative financial assets

Cash and cash equivalents comprise cash balances and call deposits with original maturities of three months or less.

The Group holds preferred shares in Amphivena designated at fair value through other comprehensive income (see note 12)

(ii)

Non-derivative financial liabilities

(iii)

Compound financial instruments

Impairment

(i)

Trade and other receivables

(ii)

Intangible assets and leasehold improvements and equipment

Income Taxes

Income taxes

Deferred tax assets and liabilities are presented net if there is a legally enforceable right to offset.

Fair Value Measurement

Level 1 – Prices for identical assets or liabilities quoted in active markets (non-adjusted)

Level 2 – Measurement procedures, in which the lowest level input parameter significant on the whole for fair value measurement is directly or indirectly observable for on the market

Level 3 – Measurement procedures, in which the lowest level input parameter significant on the whole for fair value measurement is not directly or indirectly observable for on the market

Loss Per Share

Loss per share

Loss per common share is calculated by dividing the loss of the period by the weighted average number of common shares outstanding during the period.

Critical Judgments and Accounting Estimates

Critical judgments and accounting estimates

In preparing these financial statements, the critical judgments made by management in applying the Group’s accounting policies resulted in the following accounting estimates:

(i)

Share-based payments

(ii)

Revenue recognition

The determination of whether a performance obligation is satisfied at a point in time versus over time might also requires judgment.

(iii)

Accrued expenses

(iv)

Financial instruments

New Standards and Interpretations Applied for the First Time

New standards and interpretations applied for the first time


Standard/interpretation		Effective Date 1
IFRS 15 Revenue from Contracts with Customers		January 1, 2018
IFRS 9 Financial Instruments (2014)		January 1, 2018
Amendments to IFRS 2: Classification and Measurement of Share- based Payment Transactions		January 1, 2018
Annual Improvements to IFRS Standards 2014‑2016 Cycle (IFRS 1, IAS 28)		January 1, 2018

^1.

Shall apply for periods beginning on or after the date shown in the effective date column.

The nature and effect of the application of IFRS 9 and IFRS 15 are summarized below. The other amendments had no effect on the interim consolidated financial statements of the Group.

IFRS 9 (Financial Instruments)

Classification

Combined financial instruments are measured at fair value with changes therein recognized as finance income / (costs).

Impairment

Based on this methodology, incurred losses on cash and cash equivalents and on trade and other receivables as of January 1, 2018 had no material impact on the consolidated financial statements.

IFRS 15 (Revenue from contracts with customers)

New Standards and Interpretations Not Yet Adopted

New standards and interpretations not yet adopted


Standard/Amendment		Effective Date 1
IFRS 16 Leases		January 1, 2019
Amendments to IFRS 9: Prepayment Features with Negative Compensation		January 1, 2019
Amendments to IAS 28: Long-term Interests in Associates and Joint Ventures		January 1, 2019
Annual Improvements to IFRS Standards 2015‑2017 Cycle		January 1, 2019
Amendments to IAS 19: Plan Amendment, Curtailment or Settlement		January 1, 2019
Amendments to IAS 1 and IAS 8: Definition of Material		January 1, 2020

^1.

Shall apply for periods beginning on or after the date shown in the effective date column.

IFRS 16 (Leases)

The other amended standards are not expected to have a significant effect on the consolidated financial statements of the Group.

3. Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2018

Significant Accounting Policies Policies

New Standards and Interpretations Applied for First Time


Standard/interpretation		Effective Date 1
IFRS 15 Revenue from Contracts with Customers		January 1, 2018
IFRS 9 Financial Instruments (2014)		January 1, 2018
Amendments to IFRS 2: Classification and Measurement of Share- based Payment Transactions		January 1, 2018
Annual Improvements to IFRS Standards 2014‑2016 Cycle (IFRS 1, IAS 28)		January 1, 2018

^1.

Shall apply for periods beginning on or after the date shown in the effective date column.

New Standards and Interpretations Not Yet Adopted


Standard/Amendment		Effective Date 1
IFRS 16 Leases		January 1, 2019
Amendments to IFRS 9: Prepayment Features with Negative Compensation		January 1, 2019
Amendments to IAS 28: Long-term Interests in Associates and Joint Ventures		January 1, 2019
Annual Improvements to IFRS Standards 2015‑2017 Cycle		January 1, 2019
Amendments to IAS 19: Plan Amendment, Curtailment or Settlement		January 1, 2019
Amendments to IAS 1 and IAS 8: Definition of Material		January 1, 2020

4. Segment Reporting (Tables)

12 Months Ended

Dec. 31, 2018

Segment Reporting Tables

Summary of revenue and non-current assets by geographic information


	2018	2017	2016
Revenue:
Germany	31	80	6
Europe	1,175	1,236	1,397
USA	22,529	694	4,911
	23,735	2,010	6,314

Non-current assets as of December 31:
Germany	1,224	957	618
Czech Republic	246	221	259
USA	3,825	—	—
	5,295	1,178	877

Other Revenue Information


	2018	2017	2016
Major service lines:
Collaboration revenue	22,018	390	3,866
Service revenue	1,717	1,620	2,448
	23,735	2,010	6,314

Revenue:
Point in time	21,863	233	1,191
Over time	1,872	1,777	5,123
	23,735	2,010	6,314

5. Revenue (Tables)

12 Months Ended

Dec. 31, 2018

Revenue [abstract]

Schedule of contract liabilities from customer


	January 1, 2018	December 31, 2018
Receivables	210	580
Contract liabilities	230	61,847

7. Research and Development Expenses (Tables)

12 Months Ended

Dec. 31, 2018

Research And Development Expenses Tables

Research and Development Expenses


	2018	2017	2016
Third-party services	22,127	12,299	20,170
Personnel expenses	8,055	5,639	6,648
Legal, consulting and patent expenses	1,672	890	758
Cost of materials	1,140	994	1,028
Amortisation and depreciation	351	309	322
Operating lease expenses	401	345	297
Other expenses	1,402	1,013	957
	35,148	21,489	30,180

8. General and Administrative Expenses (Tables)

12 Months Ended

Dec. 31, 2018

General And Administrative Expenses

General and Administrative Expenses


	2018	2017	2016
Personnel expenses	4,929	4,521	4,729
Legal, consulting and audit fees	2,881	1,945	2,210
Operating lease expenses	162	126	111
Other expenses	1,666	1,394	1,273
	9,638	7,986	8,323

9. Employee Benefits (Tables)

12 Months Ended

Dec. 31, 2018

Employee Benefits Tables

Employee Benefits


	2018	2017	2016
Wages and salaries	10,027	7,475	7,445
Social security costs	1,092	931	807
	11,119	8,406	8,252

10. Finance Income and Finance Costs (Tables)

12 Months Ended

Dec. 31, 2018

Finance Income And Finance Costs Tables

Finance Income and Finance Costs


	2018	2017	2016
Interest Perceptive Loan Agreement (see note 17)	—	—	(762)
Other finance cost Perceptive Loan Agreement (see note 17)	—	—	(242)
Interest SVB Loan Agreement (see note 17)	(847)	(690)	(41)
Foreign exchange differences	651	(2,378)	691
Interest on certificates of deposit with maturities of more than three months (see note 13)	5	77	122
Other finance income/finance costs	251	8	2
Finance income/costs - net	60	(2,983)	(230)

11. Income Taxes (Tables)

12 Months Ended

Dec. 31, 2018

Income Taxes Tables

Income Tax Reconciliation


	2018	2017	2016
Loss before tax	(19,476)	(30,243)	(32,274)
Income tax benefit at tax rate of 29.825 %	5,809	9,020	9,626
Adjustments due to impairment of deferred tax assets	(5,318)	(9,036)	(8,747)
Permanent differences	(462)	(93)	(948)
Adjustments for local tax rates	(34)	195	12
Non deductible expenses	(53)	16	154
Other	57	(82)	(38)
Income taxes	(1)	20	58

16. Share Based Payments (Tables)

12 Months Ended

Dec. 31, 2018

Share Based Payments Tables

Assumptions of Options Granted


	2018			2017
Fair value at grant date	$	1.20		$	1.10
Share price at grant date	$	1.91		$	2.00
Exercise price	$	1.92		$	2.03
Expected volatility		72	%		70	%
Expected life		5.90			5.90
Expected dividends		0.00			0.00
Risk-free interest rate		0.34	%		(0.23)	%

17. Borrowings (Tables)

12 Months Ended

Dec. 31, 2018

Borrowings Tables

Fair Value of Assets Pledged


	Book value as of December 31,		Book value as of December 31,
	2018		2017
	Consolidated	thereof	Consolidated
	financial	assets	financial	thereof assets
	statements	pledged	statements	pledged
Leasehold improvements and equipment	1,414	1,174	1,113	891
Inventories	260	235	241	219
Trade and other receivables	1,429	1,007	1,102	328
Other assets	387	—	800	292
Financial assets	13,974	13,974	—	—
Cash and cash equivalents	94,829	92,933	39,837	38,726
	112,293	109,323	43,093	40,456

19. Operating Leases and Other Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2018

Operating Leases And Other Commitments And Contingencies Tables

Future Minimum Lease Payment Obligations


	2018	2017
Within one year	637	470
Between one and five years	517	363
	1,154	833

20. Related Parties (Tables)

12 Months Ended

Dec. 31, 2018

Related Parties Tables

Compensation of Managing Directors and Other Key Management Personnel


	2018	2017	2016
Short-term employee benefits	2,683	1,538	1,879
Termination benefits	—	—	430
Share-based payments	1,229	1,379	2,292
	3,912	2,917	4,601

Outstanding Balances Related to Key Management Personnel


	Outstanding balances
	December 31,	December 31,
	2018	2017
Martin Treder	9	—
Leila Alland	40	—
Thomas Hecht	21	19
Richard Stead	—	12
Berndt Modig	10	9
Ferdinand Verdonck	11	10
Ulrich Grau	21	17
Bernhard Ehmer	17	10

21. Financial Risk Management (Tables)

12 Months Ended

Dec. 31, 2018

Financial Risk Management Tables

Exchange Rates


	2018	2017	2016
	CZK or	CZK or	CZK or
	USD/EUR	USD/EUR	USD/EUR
CZK - Average Rate	0.03899	0.03799	0.03699
CZK - Spot rate	0.03887	0.03916	0.03701

USD - Average Rate	0.84674	0.88519	0.90404
USD - Spot rate	0.87336	0.83382	0.94868

3. Significant Accounting Policies (Details)

12 Months Ended

Dec. 31, 2018

IFRS 16

Disclosure of initial application of standards or interpretations [line items]

Standard/amendment

IFRS 16 Leases

Effective date for new standards and interpretations not yet adopted

Jan. 01, 2019

^[1]

Amendments to IFRS 9: Prepayment Features with Negative Compensation

Disclosure of initial application of standards or interpretations [line items]

Standard/amendment

Amendments to IFRS 9: Prepayment Features with Negative Compensation

Effective date for new standards and interpretations not yet adopted

Jan. 01, 2019

^[1]

Amendments to IAS 28: Long-term Interests in Associates and Joint Ventures

Disclosure of initial application of standards or interpretations [line items]

Standard/amendment

Amendments to IAS 28: Long-term Interests in Associates and Joint Ventures

Effective date for new standards and interpretations not yet adopted

Jan. 01, 2019

^[1]

Annual Improvements to IFRS Standards 2015‑2017 Cycle

Disclosure of initial application of standards or interpretations [line items]

Standard/amendment

Annual Improvements to IFRS Standards 2015‑2017 Cycle

Effective date for new standards and interpretations not yet adopted

Jan. 01, 2019

^[1]

Amendments to IAS 19: Plan Amendment, Curtailment or Settlement

Disclosure of initial application of standards or interpretations [line items]

Standard/amendment

Amendments to IAS 19: Plan Amendment, Curtailment or Settlement

Effective date for new standards and interpretations not yet adopted

Jan. 01, 2019

^[1]

Amendments to IAS 1 and IAS 8: Definition of Material

Disclosure of initial application of standards or interpretations [line items]

Standard/amendment

Amendments to IAS 1 and IAS 8: Definition of Material

Effective date for new standards and interpretations not yet adopted

Jan. 01, 2020

^[1]

IFRS 15

Disclosure of initial application of standards or interpretations [line items]

Standard/amendment

IFRS 15 Revenue from Contracts with Customers

Effective date

Jan. 01, 2018

^[2]

IFRS 9

Disclosure of initial application of standards or interpretations [line items]

Standard/amendment

IFRS 9 Financial Instruments (2014)

Effective date

Jan. 01, 2018

^[2]

IFRS 2

Disclosure of initial application of standards or interpretations [line items]

Standard/amendment

Amendments to IFRS 2: Classification and Measurement of Share- based Payment Transactions

Effective date

Jan. 01, 2018

^[2]

Annual Improvements to IFRS Standards 2014‑2016 Cycle (IFRS 1, IAS 28)

Disclosure of initial application of standards or interpretations [line items]

Standard/amendment

Annual Improvements to IFRS Standards 2014‑2016 Cycle (IFRS 1, IAS 28)

Effective date

Jan. 01, 2018

^[2]

[1]	Shall apply for periods beginning on or after the date shown in the effective date column.
[2]	Shall apply for periods beginning on or after the date shown in the effective date column.

3. Significant Accounting Policies - Narrative (Details) - EUR (€)			12 Months Ended
	Apr. 20, 2018	Jan. 01, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Significant Accounting Policies
Impairment loss (reversal of impairment loss) recognised in profit or loss, trade receivables			€ 0	€ 0	€ 0
Dilutive effect of loan agreements and options			0
Number of share options granted in share-based payment arrangement	240,000
Vesting period (in years)	3 years
Fair value of awards granted	€ 133,000
Increase (decrease) in other comprehensive income due to transition effect		€ 7,300,000
Lease liabilities		700,000
Right-of-use assets		€ 700,000

4. Segment Reporting - Geographic information (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of operating segments [line items]
Revenues	€ 23,735	€ 2,010	€ 6,314
Non-current assets	5,295	1,178	877
Germany
Disclosure of operating segments [line items]
Revenues	31	80	6
Non-current assets	1,224	957	618
Europe
Disclosure of operating segments [line items]
Revenues	1,175	1,236	1,397
USA
Disclosure of operating segments [line items]
Revenues	22,529	694	4,911
Non-current assets	3,825
Czech Republic
Disclosure of operating segments [line items]
Non-current assets	€ 246	€ 221	€ 259

- Definition

The income arising in the course of an entity's ordinary activities. Income is increases in economic benefits during the accounting period in the form of inflows or enhancements of assets or decreases of liabilities that result in an increase in equity, other than those relating to contributions from equity participants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2017-01-01
-Paragraph 28
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=8&date=2017-03-01&anchor=para_28_a&doctype=Standard
-URIDate 2017-03-09

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2017-01-01
-Paragraph 23
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=8&date=2017-03-01&anchor=para_23_a&doctype=Standard
-URIDate 2017-03-09

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2017-01-01
-Paragraph 32
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=8&date=2017-03-01&anchor=para_32&doctype=Standard
-URIDate 2017-03-09

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2017-01-01
-Paragraph 33
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=8&date=2017-03-01&anchor=para_33_a&doctype=Standard
-URIDate 2017-03-09

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2017-01-01
-Paragraph 34
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=8&date=2017-03-01&anchor=para_34&doctype=Standard
-URIDate 2017-03-09

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2017-01-01
-Paragraph 82
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&num=1&date=2017-03-01&anchor=para_82_a&doctype=Standard
-URIDate 2017-03-09

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2017-01-01
-Paragraph 103
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&num=1&date=2017-03-01&anchor=para_103&doctype=Standard
-URIDate 2017-03-09

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Note Expiry date 2018-01-01
-Name IAS
-Number 18
-IssueDate 2017-01-01
-Paragraph 35
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&num=18&date=2017-03-02&anchor=para_35_b&doctype=Standard&book=B
-URIDate 2017-03-09

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2017-01-01
-Paragraph 102
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&num=1&date=2017-03-01&anchor=para_102&doctype=Standard
-URIDate 2017-03-09

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2017-01-01
-Paragraph B12
-Subparagraph b
-Clause v
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=12&date=2017-03-01&anchor=para_B12_b_v&doctype=Appendix&seq=2
-URIDate 2017-03-09

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2017-01-01
-Paragraph B10
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=12&date=2017-03-01&anchor=para_B10_b&doctype=Appendix&seq=2
-URIDate 2017-03-09

+ Details

4. Segment Reporting - Other revenue information (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Other revenue information
Revenues	€ 23,735	€ 2,010	€ 6,314
Point in time
Other revenue information
Revenues	21,863	233	1,191
Over time
Other revenue information
Revenues	1,872	1,777	5,123
Collaboration
Other revenue information
Revenues	22,018	390	3,866
Service
Other revenue information
Revenues	€ 1,717	€ 1,620	€ 2,448

- Definition

+ References

+ Details

4. Segment Reporting - Narrative (Details) - customer	12 Months Ended
4. Segment Reporting - Narrative (Details) - customer	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Top Three Customers
Disclosure of major customers [line items]
Number of customers			3
Top Four Customers
Disclosure of major customers [line items]
Number of customers		4
Minimum \| Top Three Customers
Disclosure of major customers [line items]
Percentage of entity's revenue			10.00%
Minimum \| Top Four Customers
Disclosure of major customers [line items]
Percentage of entity's revenue		10.00%
Minimum \| Genentech Inc.
Disclosure of major customers [line items]
Percentage of entity's revenue	10.00%

5. Revenue - Narrative (Details) € in Thousands, $ in Millions	1 Months Ended	12 Months Ended
	Oct. 31, 2018 EUR (€)	Dec. 31, 2018 EUR (€)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 EUR (€)	Dec. 31, 2016 EUR (€)	Dec. 31, 2018 USD ($)
Other revenue information
Contingent payment upon achievement of certain milestone under the collaboration agreement \| $			$ 4.4
Revenue under contract liabilities		€ 230
Additional payments upon achievement of milestones \| $						$ 5,000.0
Remaining performance obligations		€ 61,800
Performance obligations description		The remaining performance obligations at December 31, 2018 are approximately €61.8 million and are expected to be recognized as revenue to a large extent over the next two years.	The remaining performance obligations at December 31, 2018 are approximately €61.8 million and are expected to be recognized as revenue to a large extent over the next two years.
Amphivena
Other revenue information
Service fees to be received		€ 16,000
Revenue				€ 200	€ 3,400
Leukemia & Lymphoma Society
Other revenue information
Revenue		200		200	400
AbCheck
Other revenue information
Revenue		1,700		€ 1,600	€ 2,400
Genentech Inc
Other revenue information
Revenue		21,800
Collaboration agreement initial upfront payment received	€ 83,200		$ 96.0
Revenue under contract liabilities		€ 61,400

5. Revenue (Details) - EUR (€) € in Thousands	Dec. 31, 2018	Jan. 31, 2018
Revenue from Contract with Customer [Abstract]
Receivables	€ 580	€ 210
Contract liabilities	€ 61,847	€ 230

6. Other Income and Expenses - Net (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Other Income And Expenses Net Details Narrative
Income from government grants	€ 10	€ 195	€ 171
Foreign exchange gains (losses)	€ 1,523	€ (7)	€ (29)

7. Research and Development Expenses (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of Research and Development Expense [Line Items]
Research and development expenses.	€ 35,148	€ 21,489	€ 30,180
Third-party services
Disclosure of Research and Development Expense [Line Items]
Research and development expenses.	22,127	12,299	20,170
Personnel expenses
Disclosure of Research and Development Expense [Line Items]
Research and development expenses.	8,055	5,639	6,648
Legal, consulting and patent expenses
Disclosure of Research and Development Expense [Line Items]
Research and development expenses.	1,672	890	758
Costs of materials
Disclosure of Research and Development Expense [Line Items]
Research and development expenses.	1,140	994	1,028
Amortisation and depreciation
Disclosure of Research and Development Expense [Line Items]
Research and development expenses.	351	309	322
Operating lease expenses
Disclosure of Research and Development Expense [Line Items]
Research and development expenses.	401	345	297
Other expenses
Disclosure of Research and Development Expense [Line Items]
Research and development expenses.	€ 1,402	€ 1,013	€ 957

8. General and Administrative Expenses (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of General and Administrative Expense [Line Items]
General and administrative expenses	€ 9,638	€ 7,986	€ 8,323
Personnel expenses
Disclosure of General and Administrative Expense [Line Items]
General and administrative expenses	4,929	4,521	4,729
Legal, consulting and audit fees
Disclosure of General and Administrative Expense [Line Items]
General and administrative expenses	2,881	1,945	2,210
Operating lease expenses
Disclosure of General and Administrative Expense [Line Items]
General and administrative expenses	162	126	111
Other expenses
Disclosure of General and Administrative Expense [Line Items]
General and administrative expenses	€ 1,666	€ 1,394	€ 1,273

9. Employee Benefits (Details) - EUR (€) € in Thousands	12 Months Ended
9. Employee Benefits (Details) - EUR (€) € in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Employee Benefits Details
Wages and salaries	€ 10,027	€ 7,475	€ 7,445
Social security costs	1,092	931	807
Employee benefits	€ 11,119	€ 8,406	€ 8,252

10. Finance Income and Finance Costs (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of Finance Income and Finance Costs Line Items]
Finance income / (costs) - net	€ 60	€ (2,983)	€ (230)
Interest Perceptive Loan Agreement (see note 17)
Disclosure of Finance Income and Finance Costs Line Items]
Finance income / (costs) - net			(762)
Other finance cost Perceptive Loan Agreement (see note 17)
Disclosure of Finance Income and Finance Costs Line Items]
Finance income / (costs) - net			(242)
Interest SVB Loan Agreement (see note 17)
Disclosure of Finance Income and Finance Costs Line Items]
Finance income / (costs) - net	(847)	(690)	(41)
Foreign exchange differences
Disclosure of Finance Income and Finance Costs Line Items]
Finance income / (costs) - net	651	(2,378)	691
Interest certificates of deposit with maturities of more than three months (see not 14)
Disclosure of Finance Income and Finance Costs Line Items]
Finance income / (costs) - net	5	77	122
Other finance income/finance costs
Disclosure of Finance Income and Finance Costs Line Items]
Finance income / (costs) - net	€ 251	€ 8	€ 2

11. Income Taxes (Details) - EUR (€) € in Thousands	12 Months Ended
11. Income Taxes (Details) - EUR (€) € in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Taxes Details
Loss before tax	€ (19,476)	€ (30,243)	€ (32,274)
Income tax benefit at tax rate of 29.825 %	5,809	9,020	9,626
Adjustments due to impairment of deferred tax assets	(5,318)	(9,036)	(8,747)
Permanent differences	(462)	(93)	(948)
Adjustments for local tax rates	(34)	195	12
Non deductible expenses	(53)	16	154
Other	57	(82)	(38)
Income taxes	€ (1)	€ 20	€ 58

- Definition

The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax that relate to continuing operations. [Refer: Continuing operations [member]; Current tax expense (income); Deferred tax expense (income)]

+ References + Details

11. Income Taxes - Narrative (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income taxes
Income tax benefit at tax rate	29.825%
Tax loss carryforward for corporate income tax purposes	€ 163,800	€ 146,800
Maximum tax loss due to ownership changes	59,000
Tax loss carryforward for trade tax purposes	163,400	146,400
Borrowings
Income taxes
Deferred tax liabilities	75	152
Long term financial assets
Income taxes
Deferred tax liabilities	774
Trade and other receivables
Income taxes
Deferred tax assets	334	259
Trade and other payables
Income taxes
Deferred tax assets	27	17
Intangible assets
Income taxes
Deferred tax assets	415	€ 405
AbCheck
Income taxes
Tax loss carryforward for corporate income tax purposes	€ 423

12. Long term financial assets (Details) $ / shares in Units, $ in Thousands			12 Months Ended
	Dec. 05, 2018 USD ($) $ / shares shares	Jan. 01, 2018 EUR (€) $ / shares shares	Dec. 31, 2018 EUR (€) shares	Dec. 31, 2017 EUR (€) shares	Dec. 31, 2016 EUR (€)	Jun. 22, 2018 USD ($)	Dec. 27, 2017 USD ($) $ / shares shares
Disclosure of financial assets [line items]
Number of shares outstanding \| shares			62,430,106	46,791,352
Exchange rate gains			€ 1,523,000	€ (7,000)	€ (29,000)
2017 Note Purchase Agreement
Disclosure of financial assets [line items]
Principal amount \| $							$ 350
Warrants to purchase common shares \| shares							46,667
Exercise price of share \| $ / shares							$ 0.01
2018 Note Purchase Agreement
Disclosure of financial assets [line items]
Conversion of shares \| shares	389,484
Conversion price per share \| $ / shares	$ 3.59
Principal amount \| $						$ 1,000
Principal and accrued interest \| $	$ 1,400
Preferred Shares
Disclosure of financial assets [line items]
Fair value of preferred shares			€ 3,800,000
Number of shares outstanding \| shares			1,220,555
Exchange rate losses in OCI			€ 32
Change in fair value			4,700,000
Interest income			13
Exchange rate gains			€ 39
IFRS 9
Disclosure of financial assets [line items]
Financial assets recognized at fair value through other comprehensive income		€ 7,300,000
IFRS 9 \| Preferred Shares
Disclosure of financial assets [line items]
Conversion of shares \| shares		831,071
Conversion price per share \| $ / shares		€ 3.59

14. Trade and Other Receivables (Details) - EUR (€) € in Thousands	Dec. 31, 2018	Dec. 31, 2017
Disclosure of Trade and Other Receivable [Line Items]
Trade receivables	€ 210	€ 580
Overdue trade receivables		219
Value-added tax receivables
Disclosure of Trade and Other Receivable [Line Items]
Other receivables	€ 839	€ 186

15. Equity (Details) € / shares in Units, € in Thousands			3 Months Ended	12 Months Ended
15. Equity (Details) € / shares in Units, € in Thousands	Feb. 15, 2018 $ / shares shares	Feb. 15, 2018 EUR (€) shares	Mar. 31, 2018 EUR (€) shares	Dec. 31, 2018 EUR (€) € / shares shares	Dec. 31, 2017 EUR (€) € / shares shares	Dec. 31, 2016 EUR (€) shares	Jun. 19, 2018 EUR (€) € / shares shares	Jun. 18, 2018 EUR (€)	Dec. 31, 2015 EUR (€)
Issued capital \| €				€ 624	€ 468
Number of shares outstanding \| shares				62,430,106	46,791,352
par value \| € / shares				€ 0.01	€ 0.01
Number of shares issued \| shares						3,341
Proceeds from issuance of shares \| €				€ 25,113	€ 23,123	€ 6
Authorized capital \| €				40,129	31,579	38,751	€ 3,200	€ 2,196	€ 67,274
Common shares
Number of shares outstanding \| shares							155,975,000
par value \| € / shares							€ 0.01
Cumulative preference shares
Number of shares outstanding \| shares							155,975,000
par value \| € / shares							€ 0.01
Issued Capital
Authorized capital \| €				€ 624	€ 468	€ 333			€ 333
At-the-market sales agreement
Number of shares issued \| shares			2,373,716
Proceeds from issuance of shares \| €			€ 3,800
Public offering
Number of shares issued \| shares	13,225,000	13,225,000
Share price \| $ / shares	$ 2.00
Proceeds from issuance of shares \| €		€ 19,700

16. Share Based Payments (Details)		12 Months Ended
16. Share Based Payments (Details)	Apr. 20, 2018 Y	Dec. 31, 2018 USD ($) Y	Dec. 31, 2017 USD ($) Y
Share Based Payments Details
Fair value at grant date		$ 1.20	$ 1.10
Share price at grant date		1.91	2.00
Exercise price		$ 1.92	$ 2.03
Expected volatility		72.00%	70.00%
Expected life \| Y	2	5.90	5.90
Expected dividends		$ 0.00	$ 0.00
Risk-free interest rate		0.34%	(0.23%)

16. Share Based Payments - Narrative (Details)			12 Months Ended
16. Share Based Payments - Narrative (Details)	Apr. 20, 2018 EUR (€) Y tranche shares	Apr. 20, 2018 USD ($) Y tranche shares	Dec. 31, 2018 EUR (€) EquityInstruments Y USD ($) shares	Dec. 31, 2018 USD ($) EquityInstruments Y shares	Dec. 31, 2017 EUR (€) EquityInstruments Y	Dec. 31, 2017 USD ($) EquityInstruments Y	Dec. 31, 2016 EUR (€)
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period (in years)	3 years	3 years
Number of options issued \| shares	240,000	240,000
Number of tranches \| tranche	3	3
Trading days	15 days	15 days
Weighted average share price \| $				$ 1.91		$ 2.00
Grant date fair value	€ 133,000	$ 164,000
Otions life \| Y	2	2	5.90	5.90	5.90	5.90
Options exercisable \| $			0
Share based expense			€ 2,035,000		€ 1,943,000		€ 3,545,000
Tranche I
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average share price	€ 6.15
Tranche II
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average share price	8.20
Tranche III
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average share price	€ 10.25
Research and Development
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share based expense			852,000		522,000		1,178,000
General and Administrative
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share based expense			€ 1,183,000		€ 1,421,000		€ 2,367,000
ESOP 2014
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period (in years)			3 years	3 years
Awards granted \| EquityInstruments			2,332,296	2,332,296	1,436,075	1,436,075
Awards cancelled or forfeited \| EquityInstruments			424,688	424,688	399,552	399,552
Awards outstanding \| EquityInstruments			5,948,438		4,080,868
Awards exercised \| shares			40,038	40,038
Average exercise price of awards exercised \| $				$ 1.98
Awards vested \| EquityInstruments			2,814,547	2,814,547	2,001,264	2,001,264
Annual forfeiture rate			4.00%	4.00%
Weighted average remaining contractual life \| Y			9.3		8.4
Exercise period			10 years	10 years
ESOP 2014 \| Minimum
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price			€ 1.30		€ 1.80
ESOP 2014 \| Maximum
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price			€ 13.47		€ 13.47

17. Borrowings (Details) - EUR (€) € in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Disclosure of detailed information about borrowings [line items]
Leasehold improvements and equipment	€ 1,414	€ 1,113
Inventories	260	241
Trade and other receivables	1,429	1,102
Other assets	387	800
Financial assets	13,974
Cash and cash equivalents	94,829	39,837	€ 35,407	€ 76,740
Total	112,293	43,093
Thereof Assets Pledged
Disclosure of detailed information about borrowings [line items]
Leasehold improvements and equipment	1,174	891
Inventories	235	219
Trade and other receivables	1,007	328
Other assets		292
Financial assets	13,974
Cash and cash equivalents	92,933	38,726
Total	€ 109,323	€ 40,456

- Definition

The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity’s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity’s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity’s own equity instruments. For this purpose the entity’s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity’s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]

+ References + Details

17. Borrowings - Narrative (Details) € in Thousands	Nov. 30, 2016 EUR (€) tranche	Dec. 31, 2018 $ / shares	Dec. 31, 2018 EUR (€) shares	Dec. 31, 2017 $ / shares	Dec. 31, 2017 EUR (€) shares	Sep. 30, 2017 EUR (€)	May 31, 2017 EUR (€)	Dec. 31, 2016 EUR (€)
Disclosure of detailed information about borrowings [line items]
Loan payable, current			€ 3,083		€ 3,083
Silicon Valley Bank Loan [Member]
Disclosure of detailed information about borrowings [line items]
Floor rate	5.50%
Legal and arrangement fee	€ 236
Final payment fee percentage on principal	10.00%
Warrants to purchase common shares \| shares			166,297		53,395
Exercise price of share \| $ / shares		$ 2.00		$ 2.30
Expiration period	10 years
Change in fair value of warrant	€ 192
Change in deferred tax on warrant equity	81
Change in transaction cost	€ 8
Exercise period	5 years
Percentage of ownership interest pledged as security	100.00%
Fair value of financial liabilities			€ 4,773		€ 7,169
Senior Secured Term Loan Facility [Member]
Disclosure of detailed information about borrowings [line items]
Maximum borrowing capacity	€ 10,000
Number of tranches \| tranche	3
Undrawn borrowings						€ 2,500
Senior Secured Term Loan Facility Tranche One [Member]
Disclosure of detailed information about borrowings [line items]
Borrowings								€ 5,000
Senior Secured Term Loan Facility Tranche Two [Member]
Disclosure of detailed information about borrowings [line items]
Borrowings							€ 2,500
EURIBOR \| Silicon Valley Bank Loan [Member]
Disclosure of detailed information about borrowings [line items]
Variable interest rate	5.50%
Minimum \| Silicon Valley Bank Loan [Member]
Disclosure of detailed information about borrowings [line items]
Volatility	75.00%
Maximum \| Silicon Valley Bank Loan [Member]
Disclosure of detailed information about borrowings [line items]
Volatility	80.00%

18. Trade and Other Payables (Details) - EUR (€) € in Thousands	Dec. 31, 2018	Dec. 31, 2017
Trade And Other Payables Details Narrative
Trade payables	€ 8,482	€ 3,380
Other payables	€ 885	€ 514

19. Operating Leases and Other Commitments and Contingencies (Details) - EUR (€) € in Thousands	Dec. 31, 2018	Dec. 31, 2017
Disclosure of contingent liabilities [line items]
Future minimum lease payment obligations	€ 1,154	€ 833
Within one year
Disclosure of contingent liabilities [line items]
Future minimum lease payment obligations	637	470
Between one and five years
Disclosure of contingent liabilities [line items]
Future minimum lease payment obligations	€ 517	€ 363

19. Operating Leases and Other Commitments and Contingencies - Narrative (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of finance lease and operating lease by lessee [line items]
Lease expenses	€ 562	€ 472	€ 409
License fees	€ 124	€ 174	€ 405
Minimum
Disclosure of finance lease and operating lease by lessee [line items]
Lease term	1 year
Maximum
Disclosure of finance lease and operating lease by lessee [line items]
Lease term	4 years

20. Related Parties - Compensation (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Related Parties Details
Short-term employee benefits	€ 2,683	€ 1,538	€ 1,879
Termination benefits	0	0	430
Share-based payments	1,229	1,379	2,292
Key management personnel compensation	€ 3,912	€ 2,917	€ 4,601

20. Related Parties - Outstanding Balances (Details) - EUR (€) € in Thousands	Dec. 31, 2018	Dec. 31, 2017
Martin Treder
Disclosure of transactions between related parties [line items]
Key management personnel outstanding balance	€ 9
Leila Alland
Disclosure of transactions between related parties [line items]
Key management personnel outstanding balance	40
Thomas Hecht
Disclosure of transactions between related parties [line items]
Key management personnel outstanding balance	21	€ 19
Richard Stead
Disclosure of transactions between related parties [line items]
Key management personnel outstanding balance		12
Bemdt Modig
Disclosure of transactions between related parties [line items]
Key management personnel outstanding balance	10	9
Ferdinand Verdonck
Disclosure of transactions between related parties [line items]
Key management personnel outstanding balance	11	10
Ulrich Grau
Disclosure of transactions between related parties [line items]
Key management personnel outstanding balance	21	17
Bernhard Ehmer
Disclosure of transactions between related parties [line items]
Key management personnel outstanding balance	€ 17	€ 10

20. Related Parties - Narrative (Details) € in Thousands	12 Months Ended
20. Related Parties - Narrative (Details) € in Thousands	Dec. 31, 2018 EUR (€) shareholder	Dec. 31, 2017 EUR (€) shareholder	Dec. 31, 2016 EUR (€)
Disclosure of transactions between related parties [line items]
Number of shareholder holds more than 20% of the voting rights \| shareholder	0	0
Share-based expense	€ 2,035	€ 1,943	€ 3,545
Supervisory Board Directors
Disclosure of transactions between related parties [line items]
Compensation received by directors for their services	382	375	350
Share-based expense	€ 117	€ 144	381
Ulrich Grau
Disclosure of transactions between related parties [line items]
Compensation received by directors for their services			86
Jens-Peter Marschner
Disclosure of transactions between related parties [line items]
Compensation received by directors for their services			€ 29

21. Financial Risk Management - Narrative (Details) € / shares in Units, € in Thousands, $ in Millions		3 Months Ended	12 Months Ended
	Feb. 15, 2018 EUR (€) shares	Mar. 31, 2018 EUR (€) shares	Dec. 31, 2018 EUR (€) € / shares shares	Dec. 31, 2017 EUR (€) € / shares shares	Dec. 31, 2017 USD ($)	Dec. 31, 2016 EUR (€) shares	Dec. 31, 2015 EUR (€)
Disclosure of nature and extent of risks arising from financial instruments [line items]
Cash and cash equivalents			€ 94,829	€ 39,837		€ 35,407	€ 76,740
Trade and other receivables			1,429	1,102
Number of shares issued \| shares						3,341
Proceeds from issuance of shares			25,113	23,123		€ 6
Maximum foreign currency exposure			47,524	18,768
Public offering
Disclosure of nature and extent of risks arising from financial instruments [line items]
Number of shares issued \| shares	13,225,000
Proceeds from issuance of shares	€ 19,700
At-the-market sales agreement
Disclosure of nature and extent of risks arising from financial instruments [line items]
Number of shares issued \| shares		2,373,716
Proceeds from issuance of shares		€ 3,800
Credit risk
Disclosure of nature and extent of risks arising from financial instruments [line items]
Total carrying amount of shares			3,800
Convertible note and warrants of Amphivena				300
Certificates of deposit			14,000
Maximum credit exposure			114,100	€ 41,200
Interest rate risk
Disclosure of nature and extent of risks arising from financial instruments [line items]
Principal amount			7,500
Borrowings			€ 4,800
Percentage of deemed EURIBOR rate			0.00%
Floor rate			0.00%
Interest income			€ 264
Other price risk
Disclosure of nature and extent of risks arising from financial instruments [line items]
Maximum credit exposure			€ 3,800
Foreign currency risk
Disclosure of nature and extent of risks arising from financial instruments [line items]
Percentage of deviation between currency exchange rate			10.00%	10.00%	10.00%
Net loss in currency exchange deviation			€ 4,787	€ 1,887
Percentage of shift in exchange rate			10.00%
Liquidity risk \| Public offering
Disclosure of nature and extent of risks arising from financial instruments [line items]
Number of shares issued \| shares			13,225,000	10,646,762
Share price \| € / shares			€ 2.00	€ 1.80
Proceeds from issuance of shares			€ 19,700	€ 16,400
Liquidity risk \| At-the-market sales agreement
Disclosure of nature and extent of risks arising from financial instruments [line items]
Proceeds from at the market sales agreement \| $					$ 5.1
Number of shares issued \| shares			2,373,716
Proceeds from issuance of shares			€ 3,800
One Month Euribor \| Interest rate risk
Disclosure of nature and extent of risks arising from financial instruments [line items]
Variable interest rate			5.50%

21. Financial Risk Management - Exchange Rates (Details)	12 Months Ended
	Dec. 31, 2018 $ / € Kč / €	Dec. 31, 2017 $ / € Kč / €	Dec. 31, 2016 $ / € Kč / €
CZK
Disclosure of nature and extent of risks arising from financial instruments [line items]
Average rate \| Kč / €	0.03899	0.03799	0.03699
Spot rate \| Kč / €	0.03887	0.03916	0.03701
USD
Disclosure of nature and extent of risks arising from financial instruments [line items]
Average rate \| $ / €	0.84674	0.88519	0.90404
Spot rate \| $ / €	0.87336	0.83382	0.94868

Label	Element	Value
ifrs Equity, Adjusted Balance	afmd_IfrsEquityAdjustedBalance	€ 38,904,000
Revaluation surplus	ifrs-full_RevaluationSurplus	7,325,000
Retained Earnings [Member]
ifrs Equity, Adjusted Balance	afmd_IfrsEquityAdjustedBalance	(182,667,000)
Capital Reserve [Member]
ifrs Equity, Adjusted Balance	afmd_IfrsEquityAdjustedBalance	213,778,000
Issued Capital [Member]
ifrs Equity, Adjusted Balance	afmd_IfrsEquityAdjustedBalance	468,000
Revaluation Surplus [Member]
ifrs Equity, Adjusted Balance	afmd_IfrsEquityAdjustedBalance	7,325,000
Revaluation surplus	ifrs-full_RevaluationSurplus	€ 7,325,000

Consolidated Statement of Changes in Equity (Parenthetical)	Dec. 31, 2016 shares
Statement of changes in equity [abstract]
Number of shares issued	3,341

6. Other Income and Expenses - Net	12 Months Ended
6. Other Income and Expenses - Net	Dec. 31, 2018
Other Income And Expenses Net
Other Income and Expenses - Net	6. Other income and expenses - net Other income and expenses, net mainly comprises income from government grants for research and development projects of €10 (2017: €195, 2016: €171) and foreign exchange gains of €1,523 (2017: losses of €7, 2016: losses of €29).

13. Financial Assets	12 Months Ended
13. Financial Assets	Dec. 31, 2018
Financial Assets
Financial Assets	13. Financial assets As of December 31, 2018, financial assets consisted of U.S. Dollar denominated certificates of deposit with original maturities of more than three months.

14. Trade and Other Receivables	12 Months Ended
14. Trade and Other Receivables	Dec. 31, 2018
Trade and other receivables [abstract]
Trade and Other Receivables	14. Trade and other receivables The trade receivables as of December 31, 2018 and 2017, of €210 and €580, respectively, are all due in the short-term, do not bear interest and are not impaired. As of December 31, 2017, receivables of €219 were overdue. Other receivables are all due short-term and mainly comprise value-added tax receivables of €839 (2017: €186).

18. Trade and Other Payables	12 Months Ended
18. Trade and Other Payables	Dec. 31, 2018
Trade and other payables [abstract]
Trade and Other Payables	18. Trade and other payables Trade and other payables comprise trade payables of €8,482 (2017: €3,380). Other payables mainly comprise payroll and employee related liabilities for withholding taxes and social security contributions of €885 (2017: €514) and payables due to employees for outstanding bonus, unused holidays and other accruals. Other payables are normally settled within 30 days.

22. Subsequent Events	12 Months Ended
22. Subsequent Events	Dec. 31, 2018
Subsequent Events
Subsequent Events	22. Subsequent events On March 19, 2019, Affimed announced that the Group will receive a payment in an undisclosed amount on the achievement of a preclinical milestone under its ongoing strategic collaboration with Genentech.

13. Financial assets (Details)	12 Months Ended
13. Financial assets (Details)	Dec. 31, 2018
Financial Assets
Minimum Maturity period of certificate of deposits	3 months